Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

Journal of Clinical Oncology

Volumn 21, Issue 14, 2003, Pages 2636-2644

  Vogelzang, Nicholas J ^a   Rusthoven, James J ^b   Symanowski, James ^b   Denham, Claude ^b   Kaukel, E ^b   Ruffie, Pierre ^b   Gatzemeier, Ulrich ^b   Boyer, Michael ^b   Emri, Salih ^b   Manegold, Christian ^b   Niyikiza, Clef ^b   Paoletti, Paolo ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; FOLIC ACID; PEMETREXED; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; ADULT; AGED; CANCER STAGING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PLEURA TUMOR; PROBABILITY; PROGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0041629528     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.136     Document Type: Article

References (38)

1. Sugarbaker DJ, Garcia JP, Richards WG, et al: Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: Results in 120 consecutive patients. Ann Surg 224:288-296, 1996
2. Rusch VW, Venkatraman ES: Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68:1799-1804, 1999
3. Boutin C, Schlesser M, Freneay C, et al: Malignant pleural mesothelioma. Eur Respir J 12:972-981, 1998
4. Ruffie PA: Pleural mesothelioma. Curr Opin Oncol 3:328-334, 1991
5. DePangher-Manzini V, Brollo A, Franceschi S, et al: Prognostic factors of malignant mesothelioma of the pleura. Cancer 72:410-417, 1993
6. Herndon JE, Green MR, Chahinian AP, et al: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and Leukemia Group B. Chest 113:723-731, 1998
7. Law MR, Gregor A, Hodson ME, et al: Malignant mesothelioma of the pleura: A study of 52 treated and 64 untreated patients. Thorax 39:255-259, 1984
8. Sterman DH, Kaiser LR, Albelda SM: Advances in the treatment of malignant pleural mesothelioma. Chest 116:504-520, 1999
9. Ryan CW, Herndon J, Vogelzang NJ: A review of chemotherapy trials for malignant mesothelioma. Chest 113:665-735, 1998 (suppl 1)
10. Byrne MJ, Davidson JA, Musk AW, et al: Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 17:25-30, 1999
11. van Haarst JM, Baas P, Manegold CH, et al: Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86:342-345, 2002
12. Kindler HL, Millard F, Herndon JE 2nd, et al: Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 31:311-331, 2001
13. White SC, Anderson H, Jayson GC, et al: Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. Ann Oncol 11:201-206, 2000
14. van Meerbeeck JP, Baas P, Debruyne C, et al: A phase II study of gemcitabine in patients with malignant pleural mesothelioma: European Organization for Research and Treatment of Cancer, Lung Cancer Cooper-ative Group. Cancer 85:2577-2582, 1999
15. Fizazi K, Caliandro R, Soulie P, et al: Combination raltitrexed (Tomudex) oxaliplatin: A step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer 36:1514-1521, 2000
16. Sorensen PG, Bach F, Bork E, et al: Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69:1431-1432, 1985
17. Samson MK, Wasser LP, Borden EC, et al: Randomized comparison of cyclophosphamide, imidazole carboxamide, arid adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: A Sarcoma Intergroup study. J Clin Oncol 5:86-91, 1987
18. Chahinian AP, Amman K, Goutsou M, et al: Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 11:1559-1565, 1993
19. Vogelzang N, Taub R, Shin D, et al: Phase III randomized trial of onconase (One) vs. doxorubicin (Dox) in patients (pts) with unresectable malignant mesothelioma (UMM): Analysis of survival. Proc Am Soc Clin Oncol 19:577, 2000 (abstr 2274)
20. Taylor EC: Design and synthesis of inhibitors of folate-dependent enzymes as antitumor agents. Adv Exp Med Biol 338:387-408, 1993
21. Shin DM, Scagliotti GV, Kindler HL, et al: A phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: Clinical outcome, role of vitamin supplementation, respiratory symptoms and lung function. Proc Am Soc Clin Oncol 21:294, 2002 (abstr 1175)
22. Schultz RM, Chen VJ, Bewley JR, et al: Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 26:68-73, 1999 (suppl 6)
23. Mendelsohn LG, Shih C, Chen VJ, et al: Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 26:42-47, 1999 (suppl 6)
24. Moran RG: Roles of folylpoly-gamma glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: An overview. Semin Oncol 26:24-32, 1999 (suppl 6)
25. Shih C, Chen VJ, Gossett LS, et al: LY231514, a pyrrolo [2, 3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123, 1997
26. Thodtmann R, Depenbrock H, Dumez H, et al: Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17:3009-3016, 1999
27. Calvert AH, Hughes AN, Calvert PM, et al: ALIMTA in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial. Lung Cancer 29:73-74, 2000 (suppl 2)
28. Shepherd FA, Dancey J, Arnold A, et al: Phase II study of pemetrexed in patients with advanced nonsmall cell lung cancer. Cancer 92:595-600, 2001
29. Niyikiza C, Baker SD, Seitz DE, et al: Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545-552, 2002
30. Nowak AK, Byrne MJ: Assessment of response in malignant mesothelioma (MM). Proc Am Soc Clin Oncol 479a:1848, 1999 (abstr)
31. Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457-481, 1958
32. Leemis LM, Trivedi KS: A comparison of approximate interval estimators for the Bernoulli Parameter. Am Stat 50:63-68, 1996
33. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
34. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer: Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15:2996-3018, 1997
35. Vogelzang NJ, Weissman LB, Herndon JE, et al: Trimetrexate in malignant mesothelioma: A CALGB phase II study. J Clin Oncol 12:1436-1442, 1994
36. Kindler HL, Belani C, Herndon JE, et al: Edatrexate (10-ethyl- deazaaminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma: Sequential phase II trials by the Cancer and Leukemia Group B. Cancer 86:1985-1991, 1999
37. Solheim OP, Saeter G, Finnanger AM, et al: High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: A phase II study. Br J Cancer 65:956-960, 1992
38. Wang Y, Zhao R, Chattopadhyay S, et al: A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed. Cancer Res 62:6434-6437, 2002